This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Gokongwei-led Robinsons Bank has returned to the local debt market with an offering of as much as P5 billion worth of high-yielding deposits, proceeds from which will fund the bank’s aspiration to becoming one of the country’s leading banks.
JGSMY JGS RBNTF RRETY JGSHF RRHI
JG SUMMIT Holdings, Inc. is hiking its capital spending for 2018 as it aims to grow its petrochemical, airline, property, food and beverage, and banking businesses amid higher oil prices in the world market and the further depreciation of the peso.
JGSMY JGS RBNTF CEBUY UVRBY RBLAY CEBUF RLC RRETY URC CEB JGSHF UVRBF RRHI
PayMaya Philippines has partnered with the local government unit (LGU) of Muntinlupa to launch a card that the city’s residents can use to receive cash benefits and make cashless transactions.
RBNTF RRETY RRHI
Retail magnate Lucio Co-led Puregold Price Club Inc. is bowing out of the convenience store business three years after debuting into this highly competitive segment, choosing to focus on the battleground for supermarkets.
PSKXF RBNTF RRETY SEVN PHSXY PSE PHSVY RRHI
Ormoc board member Mesias Arevalo, Robinsons Land Corp. (RLC) president Frederick D. Go, RLC celebrity endorser Maja Salvador, RLC SVP/GM Arlene G. Magtibay, Robinsons Retail Holdings president Robina Gokongwei-Pe, Ormoc City Mayor Richard Gomez, Vice Mayor Toto Locsin Jr.
RLC RBNTF RRETY SYBJF RBLAY SECB RRHI
The local stock barometer pulled back to the 7,500 level on Wednesday, weighed down by local currency jitters and the downturn across US and regional markets.
SVTMF PSKXF RBNTF BDOUY AYAAY SM BDOUF BDO SMIVY ALGGY RRETY ALGGF PHSXY PSE AGI ALI AYAAF RRHI
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET